A review of nebulized drug delivery in COPD

• Published in: International journal of chronic obstructive pulmonary disease Vol. 11; no. 1; pp. 2585 - 2596
• Main Author: Tashkin, Donald P
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2016; Dove Medical Press Ltd; Dove Medical Press
• Subjects: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists - administration & dosage; Aerosols; Bronchodilator Agents - administration & dosage; Care and treatment; Chronic obstructive pulmonary disease; Drug delivery systems; Drug Delivery Systems - instrumentation; Drug dosages; Drugs; Equipment Design; Humans; Inhalers; Lung - drug effects; Lung - physiopathology; Lung diseases; Lung diseases, Obstructive; Muscarinic Antagonists - administration & dosage; nebulized drug delivery; Nebulizers and Vaporizers; Patients; pharmacologic therapy; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - physiopathology; Quality of life; Review; Testing; Trademarks; Treatment Outcome; Vehicles; United Kingdom > UK; United States > US; pharmacologic therapy; nebulized drug delivery; COPD
• ISSN: 1178-2005; 1176-9106; 1178-2005
• DOI: 10.2147/COPD.S114034

Current guidelines recommend inhaled pharmacologic therapy as the preferred route of administration for treating COPD. Bronchodilators (β -agonists and antimuscarinics) are the mainstay of pharmacologic therapy in patients with COPD, with long-acting agents recommended for patients with moderate to severe symptoms or those who are at a higher risk for COPD exacerbations. Dry powder inhalers and pressurized metered dose inhalers are the most commonly used drug delivery devices, but they may be inadequate in various clinical scenarios (eg, the elderly, the cognitively impaired, and hospitalized patients). As more drugs become available in solution formulations, patients with COPD and their caregivers are becoming increasingly satisfied with nebulized drug delivery, which provides benefits similar to drugs delivered by handheld inhalers in both symptom relief and improved quality of life. This article reviews recent innovations in nebulized drug delivery and the important role of nebulized therapy in the treatment of COPD.